Regulus Therapeutics Inc Investor Relations Material

Regulus Therapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops drugs that target microRNAs to treat a range of diseases. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.